Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Delayed Brain Radiotherapy with Almonertinib in EGFR+ NSCLC
NCT05768490Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2023
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Started Mar 2023; status: recruiting.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05768490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768490.